عربي
English
Quick links
Related sites
Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Login area | Sign up
Forgot your password? Click here
Let us help you
Read about the latest topics.
Download the new version of the MOPH app 
for the latest updates on Coronavirus
 
Be Responsible
#Raise your voice
Send us any Fraudulent Action or Enquiry so we can ALL contribute to make a Difference

Request for Quotation for Accessories for COVID-19 Vaccine

 
Country: Lebanon
Name of Project: Lebanon Health Resilience Project (LHRP)
Contract Title: Accessories for COVID-19 Vaccine
Loan No.: P163476
RFQ Reference No.: LB-MOPH-RFQ006
 
  1. The Government of Lebanon has received financing from the World Bank toward the cost of the Lebanon Health Resilience Project (LHRP) and intends to apply part of the proceeds toward payments under the contract for Procurement of Accessories for COVID-19 Vaccine. 
  2. The Lebanese Ministry of Public Health now invites quotations from eligible Bidders for syringe, latex gloves, alcohol pads, sterile NaCl ampoules, plastic sharp containers and temperature monitors to be delivered to the ministry’s warehouse at Al Quarantina Beirut within a period not exceeding one month from contract signature.
  3. Bidding will be conducted through international competitive procurement using a Request for Quotation (RFQ) as specified in the World Bank’s “Procurement Regulations for IPF Borrowers” dated July 2016 revised in November 2017 and August 2018 (“Procurement Regulations”) and is open to all eligible Bidders as defined in the Procurement Regulations.
  4. Interested eligible Bidders may obtain further information from
Agency: Ministry of Public Health
Officer: Mr. Ibrahim Assaad
Email: ibrahim.a.moph@gmail.com
  1. The quotation in English may be obtained by interested suppliers upon the submission of a written request to the address below. The document will be sent by electronic mail.
  2. Quotations must be delivered to the address below on or before Friday, March 12, 2021 at 13:00 local time. Quotations by email are acceptable. Late Bids will be rejected.
  3. The address referred to above is:
Name: Ibrahim Assaad
Title: Operations Assistant
Location: MOPH, Beer Hassan, Beirut, Lebanon
Phone number: +961 1 830 300 ext: 274
Email address: ibrahim.a.moph@gmail.com
Website: https://www.moph.gov.lb/
 
    1
    2
    3
    4
    5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
All
ATC Name B/G ↑ Ingredients Dosage Form Price
A07DA03 IMODIUM B Loperamide HCl - 2mg 2mg Capsule 138,416 L.L
A07DA03 IMODIUM INSTANTS B Loperamide HCl - 2mg 2mg Tablet, orodispersible 451,531 L.L
N02CC01 IMIGRAN B Sumatriptan (succinate) - 100mg 100mg Tablet, film coated 616,824 L.L
N02CC01 IMIGRAN B Sumatriptan (succinate) - 50mg 50mg Tablet, film coated 378,964 L.L
L04AX01 IMURAN B Azathioprine - 50mg 50mg Tablet 2,030,546 L.L
A07FA51 INFLORAN B Bifidobacterium infantis - 1milliard, Lactobacillus acidophilus - 1milliard Capsule 647,732 L.L
N05AX13 INVEGA B Paliperidone - 9mg 9mg Tablet, extended release 5,825,557 L.L
N05AX13 INVEGA B Paliperidone - 3mg 3mg Tablet, extended release 5,386,121 L.L
N05AX13 INVEGA B Paliperidone - 6mg 6mg Tablet, extended release 5,825,557 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 100mg 100mg Injectable suspension, prolonged release 17,363,826 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 75mg 75mg Injectable suspension, prolonged release 13,877,673 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 50mg 50mg Injectable suspension, prolonged release 9,661,754 L.L
N05AX13 INVEGA SUSTENNA B Paliperidone palmitate - 150mg 150mg Injectable suspension, prolonged release 25,024,258 L.L
L04AX06 IMNOVID B Pomalidomide - 2mg 2mg Capsule, hard 637,848,621 L.L
L04AX06 IMNOVID B Pomalidomide - 4mg 4mg Capsule, hard 662,450,757 L.L
M01AB01 INDOCID B Indometacin - 100mg 100mg Suppository 424,910 L.L
G03AC08 IMPLANON NXT B Etonogestrel - 68mg 68mg Implant 12,299,971 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated L.L
J01DH03 INVANZ B Ertapenem - 1g 1g Injectable concentrated powder for solution 3,785,604 L.L
L04AX06 IMNOVID B Pomalidomide - 4mg 4mg Capsule, hard L.L
C08DA01 ISOPTIN B Verapamil (HCl) - 80mg 80mg Tablet, film coated 362,150 L.L
C08DA01 ISOPTIN SR B Verapamil (HCl) - 240mg 240mg Tablet, film coated, prolonged release 1,027,907 L.L
L01EA05 ICLUSIG B Ponatinib - 15mg 15mg Tablet, film coated 103,555,839 L.L
L01EA05 ICLUSIG B Ponatinib - 45mg 45mg Tablet, film coated 207,092,651 L.L
L01EB01 IRESSA B Gefitinib - 250mg 250mg Tablet, fim coated 135,027,509 L.L
D06BA51 IALUGEN PLUS B Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 2mg/g Cream 1,064,323 L.L
D06BA51 IALUGEN PLUS B Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 0.5mg/g Gauze 1,463,444 L.L
R07AA INFASURF B Calfactant - 210mg/6ml 35mg/ml Injectable suspension 40,596,749 L.L
R07AA INFASURF B Calfactant - 105mg/3ml 35mg/ml Injectable suspension 23,344,161 L.L
L01EF01 IBRANCE B Palbociclib - 75mg 75mg Capsule 172,164,216 L.L
    1
    2
    3
    4
    5
Sitemap
© Copyrights reserved to Ministry of Public Health 2025